Pre-revenue biotech doesn’t give LP and LG the right to consistently lie and dilute shareholders to oblivion. Quite a few successful pre-revenue biotechs raise money at increasing valuations. They execute relentlessly rather than coming up with excuses and lies for well over a decade.
Nothing will change after UK approval. Once a liar always a liar!
Only pumpers that are not invested wouldn't care about ROI and are OK with losing over 90% value in the last 10-12 years.
Market Data 
Markets 
AI
